precisionFDA launches in hopes of accelerating personalized medicine

Following President Obama's call for "precision medicine," the FDA has launched precisionFDA. The initiative is an online, cloud-based portal designed to foster collaboration between multiple stakeholders in industry, academia and government. The initiative "provides a publicly accessible online portal that enables community members to conduct genome analyses for comparison against reference material, then publish the results for review," explains the Personalized Medicine Coalition, which lauded the initiative to generate knowledge for future regulatory decisions. The launch commenced with the kickoff of an initial open beta version of the portal. More from the FDA's blog | Here's reaction from the Personalized Medicine Coalition

Suggested Articles

The two companies also plan to identify new potential targets and therapeutic candidates for inflammatory bowel disease, or IBD.

This would allow centralized, lab-based diagnostic hardware to process blood samples at scale, screening patients for previous infections.

GlaxoSmithKline and AstraZeneca are considering forming a joint lab to help the U.K. expand its supplies for COVID-19 testing, according to Bloomberg.